Submission of Press Release on Audited Financial Results for FY26
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Mahamaya Lifesciences, an integrated agrochemical company, reported strong FY26 results with revenue growing 24.5% YoY to ₹32,887.30 Lakhs. EBITDA surged 32.06% to ₹3,425.88 Lakhs with margin expanding 60 bps to 10.42%. PAT grew 28.97% to ₹1,652.33 Lakhs and diluted EPS stood at ₹8.33. The company incurred ₹411 Lakhs in one-time accounting and listing-related charges (unrealized forex loss ₹264.16L, exchange difference ₹125.25L, listing expenses ₹21.57L) which weighed on H2 performance. H2 FY26 revenue was ₹16,580.93 Lakhs with EBITDA margin improving to 10.79%. Management cited strong business momentum and improved operational efficiencies as key drivers.
The company delivered robust double-digit growth across all key metrics, with margin expansion showing improved operational leverage. Despite forex and listing-related headwinds, profitability remained healthy, signaling business resilience and strength in the agrochemical sector.